Related Experiment Video

Updated: Jun 1, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4

Robert L Sutherland

    Breast Cancer Research : BCR
    |June 7, 2011
    PubMed

    Insights

    Endocrine resistance in estrogen receptor-positive breast cancer is worsened by fulvestrant, which increases ErbB-3/4 receptors. This leads to compensatory growth, compromising treatment effectiveness.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Endocrinology

    Background:

    • Endocrine resistance limits estrogen receptor-positive (ER+) breast cancer treatment.
    • Epidermal growth factor receptor (EGFR) and ErbB-2 are implicated in endocrine resistance.

    Discussion:

    • Fulvestrant treatment increases ErbB-3 and ErbB-4 levels in ER+ breast cancer cells.
    • This upregulation enhances sensitivity to heregulin β1, a ligand for ErbB-3/4.
    • Cellular plasticity enables compensatory growth stimulation via ErbB-3/4, counteracting fulvestrant's effects.

    Key Insights:

    • ErbB-3 and ErbB-4 play a significant role in endocrine resistance mechanisms.
    • Fulvestrant's efficacy is potentially undermined by compensatory signaling through ErbB-3/4.
    • Rapid growth stimulation via ErbB-3/4 compromises initial treatment benefits.

    Outlook:

    • Further research into pan-ErbB receptor inhibitors is crucial for overcoming endocrine resistance.
    • Targeting ErbB-3/4 pathways may offer novel therapeutic strategies for resistant breast cancer.
    • Evaluating ErbB-3/4 inhibitors in endocrine-resistant models is warranted.

    More Related Videos

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

    Published on: June 30, 2015

    Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

    Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

    Published on: February 21, 2014

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

    Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

    Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Metastasis02:30

    Metastasis

    Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
    Epithelial-to-Mesenchymal Transition
    The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
    Cancer-Critical Genes I: Proto-oncogenes01:33

    Cancer-Critical Genes I: Proto-oncogenes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...